- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07938814
A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).
In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Crystal Wang
- Telefonnummer: +86-021-60332455
- E-post: wangjingru@cstonepharma.com
Studiesteder
-
-
New South Wales
-
North Ryde, New South Wales, Australia, 2109
- Macquarie University
-
Hovedetterforsker:
- John Park, Dr
-
Randwick, New South Wales, Australia, 2031
- Scientia Clinical Research Ltd
-
Hovedetterforsker:
- Charlotte lemech, Dr
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Hovedetterforsker:
- Sophia Frentzas, Dr
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200123
- Shanghai East Hospital
-
Hovedetterforsker:
- Caicun Zhou
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Being ≥ 18 years of age on the day of signing informed consent.
- Pathologically or cytologically confirmed, unresectable advanced solid tumors.
- Participants must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Life expectancy ≥ 3 months.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent.
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
- Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
- Has uncontrolled pleural effusion, pericardial effusion, or ascites.
- Has immune deficient disease or received systemic immunosuppressive treatment.
- Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
- Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
- Has active infections requiring systemic therapy.
- Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
- Insufficient washout from prior anti-tumor therapy.
- Received live vaccine within 28 days prior to first dose.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- History of hypersensitivity to excipients of study drug or any monoclonal antibody.
- Any toxic effects of prior therapy unresolved to Grade ≤1.
- Pregnant or breastfeeding women.
- Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation
Participants will be administered escalating doses of CS5006. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
|
Eksperimentell: Dose Expansion
Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
[Doseutvidelse] Objektiv responsrate (ORR) evaluert av etterforskere i henhold til RECIST v1.1
Tidsramme: Opptil ca 2 år
|
Opptil ca 2 år
|
|
|
[Dose Escalation] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Tidsramme: Cycle 1 (Up to 21 Days)
|
Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT). |
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Tidsramme: Up to approximately 2 years
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range. |
Up to approximately 2 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
[Dose-eskalering] Objektiv responsrate (ORR) evaluert av etterforskere i henhold til RECIST v1.1
Tidsramme: Opptil ca 2 år
|
Opptil ca 2 år
|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Tidsramme: Up to approximately 2 years
|
Up to approximately 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CS5006-101
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .